Access : Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene : The Pharmacogenomics Journal

Access : Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene : The Pharmacogenomics Journal

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene
A Novillo et al, Pharmacogenomics Journal, October 4, 2016
(Time Posted: Oct-04-2016 2PM)

News and Commentary

The Pharmacogenomics Journal , (4 October 2016) | doi:10.1038/tpj.2016.73

• ARTICLE TOOLS

  • Send to a friend
  • Export citation
  • Rights and permissions
  • Order commercial reprints

• SEARCH PUBMED FOR

  • A Novillo
  • A Romero-Lorca
  • M Gaibar
  • M Rubio
  • A Fernández-Santander

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene

A Novillo, A Romero-Lorca, M Gaibar, M Rubio and A Fernández-Santander

Abstract

Tamoxifen (TAM) has been widely used to treat estrogen receptor (ER)-positive breast cancer, and has led to reduction of 50% in the annual recurrence rate and 30% in breast cancer mortality after 5 years of treatment.¹ The prodrug TAM is a selective ER modulator that antagonizes ERs in cancer cells. However, compared with its two active metabolites 4-hydroxy-TAM (4-OH-TAM) and endoxifen, it is a relatively weak antiestrogen.

To read this article in full you may need to log in, make a payment or gain access through a site license (see right).